Preimplantation Genetic Testing Market - Strategic Insights and Forecasts (2026-2031)

The preimplantation genetic testing market is projected to register a strong CAGR during the forecast period (2026-2031).

Market Overview

The need for preimplantation genetic testing is closely tied to IVF activity, patient age, inherited disease risk, recurrent pregnancy loss, and clinic decisions about embryo testing. The U.S. recorded 435,426 assisted reproductive technology cycles in 2022 across 457 reporting clinics, with PGT reported as a reason for 18.3% of ART cycles.

Purchasing decisions extend beyond the sequencing platform. Fertility clinics assess analytical performance, biopsy workflow, turnaround time, report interpretation, sample logistics, genetic counselling support, and the ability to combine PGT-A with PGT-M or PGT-SR. Laboratory accreditation and the reliability of results also affect supplier selection because embryo testing has direct implications for transfer decisions. ESHRE's recommendations cover patient selection, counselling, embryo biopsy, PGT-M, PGT-A, and PGT-SR, reinforcing the need for standardized clinical and laboratory practices.

PGT-A is commercially important, but evidence does not support treating it as a universal IVF requirement. The American Society for Reproductive Medicine reported in 2024 that PGT-A use in the U.S. has increased, while multicenter randomized trials found similar overall pregnancy outcomes between PGT-A and conventional IVF in the studied favorable-prognosis populations. The UK provides a different demand profile. HFEA data show that patient-reported use of PGT-A increased from 7% in 2021 to 13% in 2024, with higher use among patients aged 40 to 42.

Commercial value is distributed across embryo biopsy, sequencing, bioinformatics, laboratory testing, reporting, counselling, and related IVF services. NGS increasingly supports this value chain because a single workflow can assess chromosome copy number and, in selected configurations, monogenic variants. Technology suppliers therefore compete not only on sequencing performance but also on workflow integration, interpretation, turnaround time, and clinical support.

Key Market Indicators

Market Drivers

Integration of PGT into higher-volume IVF workflows.

U.S. ART activity provides a broad clinical base for PGT providers, while PGT was identified as a reason for 18.3% of ART cycles in 2022. Clinics increasingly need testing services that fit established biopsy, freezing, transport, and embryo-transfer workflows. Suppliers that shorten reporting time or reduce manual handling can compete on operational value as much as laboratory performance.

Rising use among patients with greater chromosomal risk.

Patient age remains commercially relevant because chromosomal abnormalities become more common with advancing maternal age. HFEA's 2024 survey found that 28% of patients aged 40 to 42 who responded had used PGT-A, compared with lower use among other age groups. This supports demand from clinics treating older IVF patients, although clinical evidence still limits the case for universal PGT-A.

Expansion of sequencing-based workflows.

NGS can support chromosome analysis and targeted variant testing within embryo-testing workflows. Thermo Fisher's reproductive-health portfolio, for example, includes NGS-based PGT research workflows capable of assessing chromosomal abnormalities and monogenic disorders from an embryo biopsy. BGI Genomics has also developed sequencing-based PGT-M and combined PGT-M/PGT-A workflows.

Demand for testing of inherited disorders.

PGT-M addresses a different clinical need from routine aneuploidy testing. Couples with a known inherited disease risk can use embryo testing to reduce transmission of a defined genetic disorder. CENTOGENE offers PGT-M alongside PGT-A and PGT-SR, while China's health authorities recognize PGT as an option for families carrying specified genetic risks. This creates demand for specialized assay design, parental testing, genetic counselling, and case-specific interpretation.

Market Restraints and Challenges

Uncertain clinical value of routine PGT-A.

ASRM's 2024 committee opinion states that the value of PGT-A as a routine screening test for all IVF patients has not been demonstrated. Randomized trials cited by ASRM found similar overall pregnancy outcomes through frozen embryo transfer in the studied populations. This evidence can make clinics cautious about broad adoption and places greater pressure on suppliers to define appropriate patient groups and communicate test limitations accurately.

Embryo biopsy and test interpretation remain technically sensitive.

PGT depends on obtaining representative embryo material and interpreting results from a small biological sample. Mosaicism, amplification limitations, no-result cases, and biological differences between the biopsied cells and the remaining embryo complicate reporting. CooperGenomics itself maintains dedicated processes around no-result cases and re-biopsy, illustrating the operational burden that laboratories must manage.

High regulatory variation limits standardization across countries.

PGT is governed by different clinical, ethical, and legal frameworks. The UK restricts embryo testing to legally permitted purposes and does not allow clinical PGT-P, while India's ART Act limits preimplantation genetic testing to known, pre-existing, heritable, or genetic diseases and prohibits sex selection except for permitted medical purposes. Such differences increase compliance work and can restrict which tests suppliers can commercialize in individual markets.

Testing cost can remain material for patients.

PGT adds laboratory and clinical costs to IVF, while coverage differs by country, indication, insurer, and treatment pathway. The UK's HFEA notes that PGT-A can be expensive and is not available through the NHS as a routine funded treatment add-on. Price sensitivity is therefore stronger in self-funded markets, increasing pressure on laboratories to demonstrate clinical and workflow value.

Major Segment Analysis

Next-generation sequencing (NGS)

Next-generation sequencing (NGS) is commercially important because it combines broad chromosome analysis with expanding capabilities for targeted genetic testing. ASRM identifies NGS alongside FISH, aCGH, SNP arrays, PCR, and other methods used for embryo ploidy assessment, while noting differences in chromosome coverage, algorithms, cost, and completion time.

Clinic buyers using NGS-based services generally value analytical performance, turnaround time, laboratory quality systems, report clarity, and compatibility with biopsy and cryopreservation workflows. The ability to support more than one testing objective from a biopsy can also improve laboratory efficiency. Thermo Fisher's ReproSeq portfolio and CooperSurgical's PGT workflows illustrate how suppliers are combining sequencing with bioinformatics and automated laboratory processes.

NGS does not remove the clinical limitations of PGT. Providers still need validated workflows, appropriate counselling, and clear interpretation of mosaic or uncertain results. Competition therefore extends from sequencing hardware into laboratory service delivery and data interpretation.

Regional Analysis

U.S. demand benefits from a large ART treatment base and extensive clinic infrastructure. CDC data show 435,426 ART cycles in 2022, while PGT was reported as a reason for 18.3% of cycles. Supplier competition is therefore supported by an established clinic and laboratory network, but ASRM's evidence review places limits on universal PGT-A adoption.

Europe has a more fragmented regulatory structure. The UK provides a clear example of evidence-led oversight, with HFEA classifying PGT-A as an add-on and reporting increased patient use from 7% in 2021 to 13% in 2024. ESHRE's technical recommendations also create a reference framework for biopsy, PGT-M, PGT-A, PGT-SR, counselling, and laboratory organization.

Asia Pacific combines established reproductive genetics markets with rapidly expanding clinical capabilities. China's authorities permit PGT only through approved assisted-reproduction institutions and have reported rising use of preimplantation genetic diagnosis. BGI has built sequencing-based PGT capabilities, while India has established a national ART framework that specifically regulates preimplantation genetic testing.

The Middle East is developing through specialist reproductive medicine and diagnostic networks. Israel provides publicly supported genetic screening and access to PGT for eligible couples, while CENTOGENE's 2026 acquisition of Pearl Medical Analysis Laboratory in Abu Dhabi expands its reproductive and genetic testing presence in the Gulf.

Competitive Landscape

The competitive structure is best described as laboratory-service and technology led, with competition extending across testing, sequencing, bioinformatics, genetic counselling, sample logistics, and clinic integration. CooperSurgical/CooperGenomics, Vitrolife/Igenomix, Natera, Thermo Fisher Scientific, Illumina, CENTOGENE, BGI Genomics, MedGenome, Fulgent Genetics, Genomic Prediction, and PacGenomics operate across different parts of the reproductive genetics value chain.

CooperSurgical combines laboratory services with PGT-A, PGT-M, PGT-SR, PGTai analysis, and clinic-facing workflows. Its 2025 UK accreditation records NGS-based PGT-A and PGT-SR processes using Illumina sequencing equipment and automated laboratory steps. CENTOGENE competes through a broader genetic-diagnostics platform and offers PGT-A, PGT-M, and PGT-SR in selected markets. BGI competes through sequencing capability and integrated reproductive-genetics workflows.

The company list supplied for this report also includes Norbrook Laboratories, Vétoquinol, Virbac, and Zoetis. These companies are animal-health businesses and do not represent direct competitors in the human preimplantation genetic testing market. They should therefore be excluded from the human PGT competitive landscape unless the report is expanded to include veterinary reproductive genetics.

Recent Developments

• July 2026: CENTOGENE took ownership of Pearl Medical Analysis Laboratory in Abu Dhabi. The transaction expands local access to reproductive and genetic testing, including PGT, and strengthens CENTOGENE's regional laboratory position.

• April 2026: GenEmbryomics and Genomic Prediction launch XGEN PGT-X™: The companies launched whole-genome embryo sequencing priced below $500 per embryo, combining GenEmbryomics’ PGT-WGS capabilities with Genomic Prediction’s polygenic embryo-testing expertise.

• October 2025: CooperSurgical introduced its Select Syndrome Screen alongside revised global PGT ordering and reporting processes, effective from January 2026. The test adds screening for selected microdeletion and microduplication syndromes to PGT workflows, while the new forms standardize ordering across regions.

• October 2025: Thermo Fisher showcased ReproSeq PGT-A solutions at the ASRM Scientific Congress, including NGS workflows designed for chromosome analysis and research applications combining chromosomal and monogenic testing. The activity reinforces the role of sequencing platforms in the expanding PGT laboratory ecosystem.

Regulatory and Policy Environment

Regulation directly affects which embryo characteristics can be tested, who can perform testing, how results are reported, and whether specific services can be offered commercially. ESHRE's PGT recommendations address patient selection, counselling, embryo biopsy, PGT-M, PGT-SR, and PGT-A, while its guideline programme is currently updating recommendations for PGT.

The UK applies particularly close oversight. HFEA states that PGT-P is not lawful because embryo testing must fall within purposes permitted by the Human Fertilisation and Embryology Act. HFEA also continues to classify PGT-A as an add-on rather than an essential component of fertility treatment.

India's ART Act creates a national framework for clinics, banks, registration, consent, record keeping, and embryo testing. Section 25 states that preimplantation genetic testing is to screen embryos for known, pre-existing, heritable, or genetic diseases, while section 26 restricts sex selection. China similarly limits assisted reproductive technologies to approved institutions and requires authorization for institutions performing preimplantation genetic diagnosis and screening.

These rules favor suppliers that can maintain accredited laboratories, documented workflows, traceable sample handling, validated assays, and strong genetic-counselling support. They also make regulatory localization an important part of international expansion.

Outlook and Strategic Implications

Demand through 2031 will remain closely linked to IVF volumes, patient age, inherited disease risk, and the willingness of clinicians and patients to pay for additional embryo information. NGS should retain a strong position because it can support broad chromosome analysis and increasingly integrated genetic workflows. However, technology expansion will not remove the need for evidence on clinical utility.

The commercial opportunity will shift toward providers that combine laboratory accuracy with faster turnaround, clear reporting, genetic counselling, sample logistics, and clinic workflow integration. Recent product activity from CooperSurgical and laboratory expansion by CENTOGENE indicate that suppliers are adding test content and geographic reach rather than competing solely on basic chromosome screening.

Three factors should shape market performance during 2026-2031:

• Clinical evidence: Suppliers will need stronger evidence on patient selection, mosaicism, and the clinical value of different testing strategies.

• Workflow economics: Clinics will favor testing models that reduce handling, shorten turnaround time, and integrate several analyses into one biopsy and reporting process.

• Regulatory localization: International suppliers will need country-specific test menus, laboratory controls, consent procedures, and reporting practices because PGT rules differ materially across markets.

For buyers, supplier selection will increasingly depend on the full testing workflow rather than sequencing technology alone. For laboratories and technology providers, differentiation will depend on validated assays, data interpretation, accreditation, turnaround time, and the ability to support increasingly complex reproductive-genetics cases. For investors, the key commercial issue is whether higher testing penetration can be sustained while clinical evidence and regulatory scrutiny place limits on routine PGT-A use.

Preimplantation Genetic Testing Market Scope: